<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00857714</url>
  </required_header>
  <id_info>
    <org_study_id>0812-11</org_study_id>
    <nct_id>NCT00857714</nct_id>
  </id_info>
  <brief_title>Lapatinib for Treatment of Ductal Carcinoma In Situ (DCIS) of the Breast</brief_title>
  <official_title>Lapatinib in the Treatment of Ductal Carcinoma in Situ of the Breast</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to establish the utility of lapatinib in the treatment of DCIS,
      particularly ER-negative DCIS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ductal carcinoma in situ (DCIS) of the breast is a pre-malignant lesion of the breast, which
      is associated with a marked increase in the likelihood of developing invasive breast cancer.
      Since DCIS tends to be associated with microcalcifications, it is detected with an increased
      frequency in patients being screened with mammographic techniques. The treatment of DCIS is
      based on a number of parameters; local treatment depends on the size of the lesion, grade and
      margins. The only systemic treatment currently available is in the form of endocrine therapy;
      it depends on the expression of estrogen receptor (ER). Randomized trials have shown that the
      treatment of DCIS with breast conserving therapy and radiation is as effective as simple
      mastectomy.

      The efficacy of tamoxifen in reducing the incidence of further invasive or non-invasive
      breast cancer has been established. In addition to surgery (with or without radiation),
      patients with ER positive disease also receive anti-estrogen therapy. Current guidelines do
      not recommend any additional therapy for ER-negative DCIS.

      The rationale for the proposed study is based on the observations that HER2 is expressed at
      high levels in higher grades of DCIS, which typically lack ER. In addition, an inverse
      relationship between ER expression and the expression of EGFR has also been demonstrated.
      Lapatinib is active against both these receptors and may have therapeutic action in ER
      negative DCIS.

      We propose to treat the patients with drug in the interval between biopsy diagnosis and
      definitive surgery.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Terminated due to low accrual
  </why_stopped>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients Where Gene Signature Was Obtained.</measure>
    <time_frame>Up to 60 days</time_frame>
    <description>Number of patients where gene signature was obtained. This was used to identify gene signature that denotes effect of lapatinib therapy in breast cancer cell lines and to assess effect of lapatinib therapy in patients with ductal carinoma in situ of the breast using the gene signature developed as a surrogate marker.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Toxicity Associated With Short Therapy With Lapatinib.</measure>
    <time_frame>Up to 60 days</time_frame>
    <description>Number of patients with toxicity associated with short therapy with lapatinib will be reported.</description>
  </secondary_outcome>
  <enrollment type="Actual">1</enrollment>
  <condition>Ductal Carcinoma in Situ</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lapatinib</intervention_name>
    <description>1500 mg lapatinib for 14-21 days</description>
    <other_name>Tykerb</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age greater than or equal to 18 years.

          2. Patients with operable, biopsy-proven DCIS detected by screening mammography.

          3. ER/PR negative DCIS.

          4. DCIS that is positive for HER-2 &amp;/or EGFR, which is defined as IHC 3+.

          5. Women of childbearing potential willing to use an accepted and effective barrier
             method of contraception.

          6. ECOG performance status ≤2

          7. Cardiac ejection fraction within the institutional range of normal as measured by
             echocardiogram.

          8. Ability to understand and the willingness to sign a written informed consent document.

          9. Patients must have normal organ and marrow function as defined below:

               -  leukocytes ≥3,000/microL

               -  absolute neutrophil count ≥1,500/microL

               -  platelets ≥100,000/microL

               -  total bilirubin within normal institutional limits

               -  AST (SGOT)/ALT(SGPT) within normal institutional limits

               -  creatinine within normal institutional limits OR creatinine clearance greater
                  than or equal to 60 mL/min/1.73 m2 for patients with creatinine levels above
                  institutional normal (using Cockcroft-Gault formula)

        Exclusion Criteria:

          1. Invasive breast cancer

          2. ER+ or PR+ DCIS

          3. Pregnant or breast feeding women

          4. Patients who have had prior treatment with EGFR targeting therapies.

          5. Patients may not be receiving any other investigational agents or receiving concurrent
             anticancer therapy. In addition, all herbal (alternative) medicines are excluded one
             week before starting lapatinib and for the duration of lapatinib therapy.

          6. Uncontrolled inter-current illness including, but not limited to, ongoing or active
             infection, or psychiatric illness/social situations that would limit compliance with
             study requirements.

          7. HIV-positive patients receiving combination anti-retroviral therapy are excluded from
             the study because of possible pharmacokinetic interactions with lapatinib.

          8. Have ANY hepatic or biliary disease or dysfunction.

          9. Patients with GI tract disease resulting in an inability to take oral medication,
             malabsorption syndrome, a requirement for IV alimentation, prior surgical procedures
             affecting absorption, uncontrolled inflammatory GI disease (e.g., Crohn's, ulcerative
             colitis).

         10. Concomitant requirement for medication classified as CYP3A4 inducers or inhibitors.

         11. ANY history of cardiac disease.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sunil Badve, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2009</study_first_submitted>
  <study_first_submitted_qc>March 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2009</study_first_posted>
  <results_first_submitted>June 16, 2015</results_first_submitted>
  <results_first_submitted_qc>June 16, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 8, 2015</results_first_posted>
  <last_update_submitted>June 16, 2015</last_update_submitted>
  <last_update_submitted_qc>June 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DCIS</keyword>
  <keyword>breast</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma in Situ</mesh_term>
    <mesh_term>Carcinoma, Ductal</mesh_term>
    <mesh_term>Carcinoma, Intraductal, Noninfiltrating</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lapatinib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Thirty patients were expected for this trial but it stopped at one patient due to difficulty with recruitment.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>1500 mg Lapatinib for 14-21 Days</title>
          <description>Patients took 1500 mg Lapatinib for 14-21 days until surgical excision.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>1500 mg Lapatinib for 14-21 Days</title>
          <description>Patients took 1500 mg Lapatinib for 14-21 days until surgical excision.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63">Only one patient available; standard deviation cannot be calculated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients Where Gene Signature Was Obtained.</title>
        <description>Number of patients where gene signature was obtained. This was used to identify gene signature that denotes effect of lapatinib therapy in breast cancer cell lines and to assess effect of lapatinib therapy in patients with ductal carinoma in situ of the breast using the gene signature developed as a surrogate marker.</description>
        <time_frame>Up to 60 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1500 mg Lapatinib for 14-21 Days</title>
            <description>Patients took 1500 mg Lapatinib for 14-21 days until surgical excision.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Where Gene Signature Was Obtained.</title>
          <description>Number of patients where gene signature was obtained. This was used to identify gene signature that denotes effect of lapatinib therapy in breast cancer cell lines and to assess effect of lapatinib therapy in patients with ductal carinoma in situ of the breast using the gene signature developed as a surrogate marker.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Toxicity Associated With Short Therapy With Lapatinib.</title>
        <description>Number of patients with toxicity associated with short therapy with lapatinib will be reported.</description>
        <time_frame>Up to 60 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1500 mg Lapatinib for 14-21 Days</title>
            <description>Patients took 1500 mg Lapatinib for 14-21 days until surgical excision.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Toxicity Associated With Short Therapy With Lapatinib.</title>
          <description>Number of patients with toxicity associated with short therapy with lapatinib will be reported.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 60 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>1500 mg Lapatinib for 14-21 Days</title>
          <description>Patients took 1500 mg Lapatinib for 14-21 days until surgical excision.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (9.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Wound complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (9.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>mouth sores</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>cramping</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>skin rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>nail changes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sunil Badve, MD</name_or_title>
      <organization>IndianaU</organization>
      <phone>317-491-6417</phone>
      <email>sbadve@iupui.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

